Nirvana Life Sciences Ratios and Metrics

Market cap in millions CAD. Fiscal year is May - April.

Millions CAD. Fiscal year is May - Apr.

Fiscal Year	Current	FY 2023	FY 2022	FY 2021
Period Ending	Sep '24 Sep 25, 2024	Apr '23 Apr 30, 2023	Apr '22 Apr 30, 2022	Apr '21 Apr 30, 2021
Market Capitalization	4	1	4	-
Market Cap Growth	-44.54%	-74.83%	-	-
Enterprise Value	4	1	4	-
Last Close Price	0.07	0.03	0.57	-
PE Ratio	-	-0.68	-3.68	-
PB Ratio	-2.66	-1.09	-25.10	-
P/FCF Ratio	-8.59	-3.06	-8.27	-
P/OCF Ratio	-8.59	-3.06	-8.27	-
EV/EBITDA Ratio	-2.36	-1.01	-3.69	-
EV/EBIT Ratio	-2.28	-0.93	-3.40	-
EV/FCF Ratio	-8.62	-3.30	-8.07	-
Debt / Equity Ratio	-0.03	-0.06	-	-
Debt / FCF Ratio	-0.09	-0.18	-	-
Quick Ratio	0.02	0.03	0.08	34.85
Current Ratio	0.05	0.07	0.22	42.41
Return on Equity (ROE)	-	-	-1105.54%	-
Return on Assets (ROA)	-197.82%	-264.67%	-86.15%	-
Return on Capital (ROIC)	-	-	-142.24%	-
Earnings Yield	-37.96%	-145.67%	-139.42%	-
FCF Yield	-11.64%	-32.64%	-12.09%	-
Buyback Yield / Dilution	-31.20%	7.05%	-5.19%	-
Total Shareholder Return	-31.20%	7.05%	-5.19%	-

Source: S&P Capital IQ. Standard template. Financial Sources.